These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 19667670)

  • 21. Impact of obesity on the pathogenesis and prognosis of coronary heart disease.
    Todd Miller M; Lavie CJ; White CJ
    J Cardiometab Syndr; 2008; 3(3):162-7. PubMed ID: 18983333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHD risk equivalents and the metabolic syndrome. Trial evidence supports aggressive management.
    Thompson PD
    Postgrad Med; 2003 Aug; 114(2 Suppl):22-30. PubMed ID: 19667636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significance of HDL cholesterol increase for the risk reduction. Methods of intervention. recommendations of experts].
    Kardiol Pol; 2005 Jun; 62 Suppl 2():II5-12. PubMed ID: 19813328
    [No Abstract]   [Full Text] [Related]  

  • 24. The patient with CHD: how should we translate international guidelines into clinical practice?
    Schwandt P; Betteridge J; Erkelens W; Mancini M; Ochsenhirt B; Parhofer KG; Paulweber B; Saner H; Volta SD
    Nutr Metab Cardiovasc Dis; 2000 Apr; 10(2):79-84. PubMed ID: 10919172
    [No Abstract]   [Full Text] [Related]  

  • 25. Strategies for optimizing lipid management.
    Ballantyne CM
    Postgrad Med; 2004 Sep; 116(3 Suppl):13-20. PubMed ID: 19667671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of coronary and contributory risk factors in rural and urban type 2 diabetics.
    Jha N
    Kathmandu Univ Med J (KUMJ); 2004; 2(1):28-34. PubMed ID: 19780285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evidence for global CHD risk calculation: risk assessment alone does not change outcomes.
    Ham P
    Am Fam Physician; 2010 Aug; 82(3):236. PubMed ID: 20672785
    [No Abstract]   [Full Text] [Related]  

  • 29. Improving outcomes in high-risk populations using REACH: an inpatient cardiac risk reduction program.
    Patel PV; Gilski D; Morrison J
    Crit Pathw Cardiol; 2009 Sep; 8(3):112-8. PubMed ID: 19726930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The metabolic syndrome as a risk factor for venous and arterial thrombosis.
    Dentali F; Squizzato A; Ageno W
    Semin Thromb Hemost; 2009 Jul; 35(5):451-7. PubMed ID: 19739035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aspirin therapy now recommended for people at risk for heart disease.
    Rollins G
    Rep Med Guidel Outcomes Res; 2002 Feb; 13(3):1-2, 5. PubMed ID: 12428631
    [No Abstract]   [Full Text] [Related]  

  • 32. Using nontraditional risk factors in coronary heart disease risk assessment.
    Lin KW; Garcia SM
    Am Fam Physician; 2011 Feb; 83(4):449. PubMed ID: 21322521
    [No Abstract]   [Full Text] [Related]  

  • 33. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG
    J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome evaluation of a structured educational wellness program in patients with severe mental illness.
    Lindenmayer JP; Khan A; Wance D; Maccabee N; Kaushik S; Kaushik S
    J Clin Psychiatry; 2009 Oct; 70(10):1385-96. PubMed ID: 19778494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of CHD: the role of elevated triglycerides.
    Watson KE
    J Am Acad Nurse Pract; 2007; 19(12 Suppl 2):4-6, 13-4. PubMed ID: 18510281
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia.
    Gündogan K; Bayram F; Capak M; Tanriverdi F; Karaman A; Ozturk A; Altunbas H; Gökce C; Kalkan A; Yazici C
    Metab Syndr Relat Disord; 2009 Oct; 7(5):427-34. PubMed ID: 19754305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors.
    Güder G; Frantz S; Bauersachs J; Allolio B; Wanner C; Koller MT; Ertl G; Angermann CE; Störk S
    Circ Heart Fail; 2009 Nov; 2(6):563-71. PubMed ID: 19919981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Doctors at the heart of this cardiac DM program's success.
    Healthc Demand Dis Manag; 1999 Jun; 5(6):90-1. PubMed ID: 10538687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Millions of healthy people can be considered ill because of the American cholesterol policy].
    Ravnskov U
    Lakartidningen; 2001 Oct; 98(42):4574-7. PubMed ID: 11715230
    [No Abstract]   [Full Text] [Related]  

  • 40. Perspective: risk apportionment and disease intervention strategies.
    Barraj LM; Tran NL; Goodman M; Ginevan ME
    Risk Anal; 2008 Apr; 28(2):477-86. PubMed ID: 18419663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.